Table 1.
Demographic and baseline clinical characteristics
| Characteristic | ATL-DC | GAA-DC |
|---|---|---|
| (N=28) | (N=6) | |
| AGE – yr | 49 | 44 |
| Gender | ||
| • Male | 20 | 6 |
| • Female | 8 | 0 |
| KPS (@ DC vacc.) | 90 | 80 |
| Tumor Pathology | ||
| • Glioblastoma (WHO Grade IV) | 23 (82.1) | 4 (66) |
| • Anaplastic glioma (WHO Grade III) | 5 (17.9) | 2 (33) |
| Tumor Characteristics | ||
| • IDH1 (% mutated) | 17 | 50 |
| Time to Treatment* (months) | 4.9+/-4.1 | 4.4+/-1.8 |
| Survival Characteristics | ||
| • OS (months) | 34.4 | 14.5 |
| • PFS (months) | 18.1 | 9.6 |
*
Time interval from the date of surgery until date of 1st DC vaccination in months +/- standard deviation.